NuCana had a loss last quarter and shared updates on its products and patents.

Nov 13, 2026, 4:03 AM ETResultsRead the original at globenewswire.com

Neutral

NuCana's quarterly loss grew from £0.3 million to £1.6 million, but it had £18.3 million in cash and expects funds to last into 2029. The European patent adds protection, but no trial results were reported, so the facts do not clearly shift its outlook.

NCNA · NuCana plc

AI read · Neutral

The AI's read

The cash balance gives NuCana time to keep working on its cancer drug candidates. The larger loss weighs against that support. The update gives no trial findings showing whether either candidate is helping patients. The patent adds protection, but the report gives no evidence of sales or treatment progress.

Get alerts for NCNA

Follow NuCana plc (NCNA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NCNA

Free on the App Store and Google Play, or on the web.